AbbVie turned in better-than-expected second quarter results, but investors remained focused on whether pipeline prospects will make up for the eventual decline of Humira.
AbbVie’s Richard Gonzalez scored a bit of a raise last year, to $20.97 million from $20.81 million, thanks to an increase in incentive pay, a slight bump in base salary and a boost to his personal air travel.
AbbVie investors were relieved when the company announced first-quarter results that exceeded forecasts, driven largely by an increase in Humira sales.
